138 related articles for article (PubMed ID: 17130576)
1. DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes.
Elias D; Avron A; Tamir M; Raz I
Ann N Y Acad Sci; 2006 Oct; 1079():340-4. PubMed ID: 17130576
[TBL] [Abstract][Full Text] [Related]
2. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.
Raz I; Avron A; Tamir M; Metzger M; Symer L; Eldor R; Cohen IR; Elias D
Diabetes Metab Res Rev; 2007 May; 23(4):292-8. PubMed ID: 17124720
[TBL] [Abstract][Full Text] [Related]
3. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.
Schloot NC; Meierhoff G; Lengyel C; Vándorfi G; Takács J; Pánczél P; Barkai L; Madácsy L; Oroszlán T; Kovács P; Sütö G; Battelino T; Hosszufalusi N; Jermendy G
Diabetes Metab Res Rev; 2007 May; 23(4):276-85. PubMed ID: 17103487
[TBL] [Abstract][Full Text] [Related]
4. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study.
Lazar L; Ofan R; Weintrob N; Avron A; Tamir M; Elias D; Phillip M; Josefsberg Z
Diabetes Metab Res Rev; 2007 May; 23(4):286-91. PubMed ID: 17124721
[TBL] [Abstract][Full Text] [Related]
5. C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study.
Buzzetti R; Cernea S; Petrone A; Capizzi M; Spoletini M; Zampetti S; Guglielmi C; Venditti C; Pozzilli P;
Diabetes; 2011 Nov; 60(11):3067-72. PubMed ID: 21896927
[TBL] [Abstract][Full Text] [Related]
6. Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients.
Huurman VA; Decochez K; Mathieu C; Cohen IR; Roep BO
Diabetes Metab Res Rev; 2007 May; 23(4):269-75. PubMed ID: 17024692
[TBL] [Abstract][Full Text] [Related]
7. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.
Raz I; Elias D; Avron A; Tamir M; Metzger M; Cohen IR
Lancet; 2001 Nov; 358(9295):1749-53. PubMed ID: 11734230
[TBL] [Abstract][Full Text] [Related]
8. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results.
Eldor R; Kassem S; Raz I
Diabetes Metab Res Rev; 2009 May; 25(4):316-20. PubMed ID: 19267355
[TBL] [Abstract][Full Text] [Related]
9. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes.
Huurman VA; van der Meide PE; Duinkerken G; Willemen S; Cohen IR; Elias D; Roep BO
Clin Exp Immunol; 2008 Jun; 152(3):488-97. PubMed ID: 18422727
[TBL] [Abstract][Full Text] [Related]
10. DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes.
Tuccinardi D; Fioriti E; Manfrini S; D'Amico E; Pozzilli P
Expert Opin Biol Ther; 2011 Sep; 11(9):1233-40. PubMed ID: 21751937
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal.
Pozzilli P; Raz I; Peled D; Elias D; Avron A; Tamir M; Eren R; Dagan S; Cohen IR
Diabetes Care; 2014; 37(5):1384-91. PubMed ID: 24408401
[TBL] [Abstract][Full Text] [Related]
12. DiaPep277 (DeveloGen).
Giannoukakis N
Curr Opin Investig Drugs; 2005 Oct; 6(10):1043-50. PubMed ID: 16259226
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulation with heat shock protein DiaPep277 to preserve beta cell function in type 1 diabetes - an update.
Fischer B; Elias D; Bretzel RG; Linn T
Expert Opin Biol Ther; 2010 Feb; 10(2):265-72. PubMed ID: 20034363
[TBL] [Abstract][Full Text] [Related]
14. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.
Quattrin T; Haller MJ; Steck AK; Felner EI; Li Y; Xia Y; Leu JH; Zoka R; Hedrick JA; Rigby MR; Vercruysse F;
N Engl J Med; 2020 Nov; 383(21):2007-2017. PubMed ID: 33207093
[TBL] [Abstract][Full Text] [Related]
15. Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP).
Dungan KM; Buse JB; Ratner RE
Diabetes Metab Res Rev; 2009 Sep; 25(6):558-65. PubMed ID: 19626663
[TBL] [Abstract][Full Text] [Related]
16. DiaPep277® and immune intervention for treatment of type 1 diabetes.
Schloot NC; Cohen IR
Clin Immunol; 2013 Dec; 149(3):307-16. PubMed ID: 24090708
[TBL] [Abstract][Full Text] [Related]
17. Persistent C-peptide is associated with reduced hypoglycaemia but not HbA
Marren SM; Hammersley S; McDonald TJ; Shields BM; Knight BA; Hill A; Bolt R; Tree TI; Roep BO; Hattersley AT; Jones AG; Oram RA;
Diabet Med; 2019 Sep; 36(9):1092-1099. PubMed ID: 30955221
[TBL] [Abstract][Full Text] [Related]
18. Effect of pioglitazone on the course of new-onset type 1 diabetes mellitus.
Tafuri KS; Godil MA; Lane AH; Wilson TA
J Clin Res Pediatr Endocrinol; 2013; 5(4):236-9. PubMed ID: 24379032
[TBL] [Abstract][Full Text] [Related]
19. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.
Walter M; Philotheou A; Bonnici F; Ziegler AG; Jimenez R;
Diabetes Care; 2009 Nov; 32(11):2036-40. PubMed ID: 19690081
[TBL] [Abstract][Full Text] [Related]
20. Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose.
Hao W; Gitelman S; DiMeglio LA; Boulware D; Greenbaum CJ;
Diabetes Care; 2016 Oct; 39(10):1664-70. PubMed ID: 27422577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
